Drug intelligence / Profile preview

Fuqing Xuelian Suppository

Development stage: Unknown
Lead developer: Guangzhou Hanfang Pharmaceutical
Modality: Small Molecules
Administration: Vaginal

Overview

Fuqing Xuelian Suppository (妇清雪莲栓) is a Traditional Chinese Medicine (TCM) developed by Guangzhou Baiyunshan Hanfang Modern Chinese Medicine for the treatment of bacterial vaginitis. Formulated as a vaginal suppository, the drug utilizes herbal extracts, primarily from Snow Lotus (*Saussurea involucrata*), which are known for their antimicrobial and anti-inflammatory properties. The therapeutic objective is to eliminate pathogenic bacteria in the vaginal tract and reduce local inflammation, thereby restoring the physiological microecological balance. It is currently in Phase 3 clinical development in China.

Brand names: Fuqing Xuelian Suppository妇清雪莲栓
Other names: Fuqing Xuelian Shuan

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on Fuqing Xuelian Suppository.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuqing Xuelian Suppository.

Explore the full profile